J&J Sets The Pace In Race To $10bn RSV Vaccine Market

80% Efficacy Against Severe Disease In 65+ Group

Oct 04 2021

GSK and Pfizer have already begun Phase III studies, but J&J's Phase II results are the most compelling so far.